Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist

Stroke

Volumn 31, Issue 2, 2000, Pages 347-354

  Davis, Stephen M ^b   Lees, Kennedy R ^c   Albers, Gregory W ^a   Diener, Hans Christoph ^c   Markabi, Sabri ^c   Karlsson, Goeril ^c   Norris, John ^c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c NONE

Author keywords

Controlled clinical trials; Neuroprotection; Stroke, acute; Stroke, ischemic

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID;

ACUTE DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033951941     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.31.2.347     Document Type: Article

References (30)

1. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 1997;49(5 suppl 4):S66-S69.
2. Markabi S. Selfotel (CGS.5): The preliminary clinical experience. In: Krieglstein J, Oberpichler-Schwenk H, eds. Pharmacology of Cerebral Ischemia. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH; 1994:635-642.
3. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke. 1995;26:602-605.
4. Gotti B, Benavides J, MacKenzie ET, Scatton B. The pharmacotherapy of focal cortical ischaemia in the mouse. Brain Res. 1990;522:290-307.
5. Simon R, Shiraishi K. N-methyl-D-aspartate antagonist reduces stroke size and regional glucose metabolism. Ann Neurol. 1990;27:606-611.
6. Sauer D, Allegrini PR, Cosenti A, Pataki A, Amacker H, Fagg GE. Characterization of the cerebroprotective efficacy of the competitive NMDA receptor antagonist CGP-40116 in a rat model of focal cerebral ischemia: an in vivo magnetic resonance imaging study. J Cereb Blood Flow Metab. 13:595-602.
7. Simmonds J, Sailer T, Moyer J. The effects of CGS-19755 in rat focal cerebral ischemia produced by tandem ipsilateral common carotid artery and middle cerebral artery occlusion. Soc Neurosci Abstr. 1993;19:1647. Abstract.
8. Madden K, Clark W, Zivin J. Delayed therapy of experimental ischemia with competitive N-methyl-D-aspartate antagonists in rabbits. Stroke. 1993;24:1068-1071.
9. Takizawa S, Hogan M, Hakim A. The effects of a competitive NMDA receptor antagonist (CGS-19755) on cerebral blood flow and pH in focal ischemia. J Cereb Blood Flow Metab. 1991;11:786-793.
10. Mahoney FI, and Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;61-65.
11. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
12. Scandinavian Stroke Study Group. Multicenter Trial of Hemodilution in Ischemic Stroke: background and study protocol. Stroke. 1985;16:881-890.
13. Fleiss JL. Statistical Methods for Rate and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981.
14. Davis SM, Albers GW, Diener, Lees KR, Norris J (ASSIST Steering Committee). Termination of acute stroke studies involving Selfotel treatment. Lancet. 1997;349:32. Letter.
15. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 1995;26:254-258.
16. Minematsu K, Fisher M, Li L, Davis MA, Knapp AG, Cotter RE, McBurney RN, Sotak CH. Effects of a novel MNDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology. 1993;43:397-403.
17. Fisher M, for CNS 1102-003 Investigators. Cerestat (CNS 1102), a non-competitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study. Cerebrovasc Dis. 1994;4:245.
18. Edwards D, and the CNS 1102-008 Study Group. Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: results of a phase II trial. Neurology. 1996;46:A424. Abstract.
19. Turrini R. A pivotal safety and efficacy study of Cerestat™ (Aptiganel HCL/CNS) in acute ischemic stroke. Stroke. 1996;27:173. Abstract.
20. Wahlgren NG. Pharmacological treatment of acute stroke. Cerebrovasc Dis. 1997;7:24-30.
21. Diener HC. The failure of NMDA antagonists. In: Current Approaches to Acute Stroke Management. Excerpta Medica; 1997;5:12-14.
22. Olney JW. Neurotoxicity of NMDA receptor antagonists: an overview. Psychopharmacol Bull. 1994;30:533-540.
23. Grotta J. Why do all drugs work in animals but none in stroke patients? 2: neuroprotective therapy. J Intern Med. 1995;237:89-94.
24. Hossman KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol. 1994;36:557-565.
25. Loscher W, Wlaz P, Szabo L. Focal ischemia enhances the adverse effect potential of N-methyl-D-aspartate receptor antagonists in rats. Neurosci Lett. 1998;240:33-36.
26. Grotta J. The current status of neuronal protective therapy: why have all neuronal protective drugs worked in animals but none so far in stroke patients? Cerebrovasc Dis. 1994;4:115-120.
27. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl Med. 1995;333:1581-1587.
28. Sherman DG, for the STAT Writers Group. Defibrinogenation with Viprinex™ (ANCROD) for the treatment of acute ischemic stroke. Stroke. 1999;30:234. Abstract.
29. Grotta JC. Acute stroke therapy at the millennium: consummating the marriage between the laboratory and bedside: the Feinberg Lecture. Stroke. 1999;30:1722-1728.
30. Heiss WD, Thiel A, Grond R. Which targets are relevant for therapy of acute ischemic stroke? Stroke. 1999;30:1486-1489.